China Human Vaccine Industry Report, 2018-2022
  • Oct.2018
  • Hard Copy
  • USD $3,200
  • Pages:155
  • Single User License
    (PDF Unprintable)       
  • USD $3,000
  • Code: ZLC068
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,500
  • Hard Copy + Single User License
  • USD $3,400
      

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.

The lot release volume of human vaccines has remained at around 650 million doses over the past three years. China Food and Drug Administration (CFDA) approved the launch of 9-valent human papillomavirus vaccine (saccharomyces cerevisiae) and oral 5-valent reassortant rotavirus attenuated live vaccine (Vero cell) in the first half of 2018. The National Institutes for Food and Drug Control, Hubei Institute for Food and Drug Control, and Shanghai Institute for Food and Drug Control approved supply of 434.1 million doses (44 kinds of vaccines) to the market from January to September 2018.

With annual capacity of over one billion doses, more than forty vaccine manufacturers in China are capable of producing 63 kinds of vaccines for prevention of 34 sorts of infectious diseases. Among them, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Changchun Institute of Biological Products, Beijing Bio-Institute Biological Products, Changchun KEYGEN Biological Products, and Beijing Tiantan Biological Products (Beijing Tiantan Biological Products has no vaccine business after completion of asset restructuring in May 2017) under China National Biotech Group Co., Ltd. occupy half of the Chinese vaccine market. The subsidiaries under China National Biotech Group Co., Ltd. recorded lot release volume of 349.147 million doses in 2017 and 198.261 million doses in the first nine months of 2018, making up 53.1% and 45.7% of the country’s total amount, respectively.

vaccine 1_副本.png

In recent years, Chinese vaccine companies have spared no efforts in research and development to sharpen competitiveness. As yet, not a Chinese enterprise can produce HPV vaccines and 13-valent pneumonia vaccines, but local companies including Walvax Biotechnology and Shenzhen Kangtai Biological Products are developing such vaccines which are expected to be available soon.

With the implementation of two-child policy, the aging of population and the launch of new-type vaccines, China’s human vaccine industry will grow steadily in future, with the expected market size of RMB35.2 billion by 2022. Meanwhile, vaccine companies with richer capital and stronger R&D strength will give play to technological superiorities and scale effect, and raise their market share through capital operation and other means. In this sense, China’s vaccine industry tends to feature higher and higher concentration.

vaccine 2_副本.png

China Human Vaccine Industry Report, 2018-2022 highlights the following:
20120114.gifChina’s human vaccine industry (operating environment, status quo, market demand, distribution channels, market size, import and export, and competitive landscape);
20120114.gifChinese human vaccine market segments (market demand, lot release volume and competitive landscape);
20120114.gif22 human vaccine companies (operation, R&D and investment, development strategy, etc.) .

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.3 Hepatitis A Vaccine
3.3.1 Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.5 Hib Vaccine
3.5.1 Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.6 Human Rabies Vaccine
3.6.1 Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.7 Varicella Vaccine
3.7.1 Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.8 Pneumococcal Vaccines
3.8.1 Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.9 DTP Vaccine
3.9.1 Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.10 Poliomyelitis Vaccine
3.10.1 Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.11 Hepatitis E Vaccine
3.11.1 Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern

4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine and Serum Institute 
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.2 Beijing Tiantan Biological Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D
4.2.6 Vaccine Business
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D
4.3.5 Vaccine Business
4.3.6 Development Strategy
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D
4.4.6 Development Dynamics
4.4.7 Development Strategy
4.5 Walvax Biotechnology Co, Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D
4.5.6 Vaccine Business
4.5.7 Development Trend
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 R&D
4.6.7 Development Strategy
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D
4.7.6 Development Strategy
4.8 Changsheng Bio-Technology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D
4.8.5 Development Dynamics
4.9 Olymvax Biopharmaceuticals Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 R&D
4.10 Sinovac Biotech Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Sinovac Biotech (Beijing)
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Development Dynamics
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.13 Dalian Hissen Bio-Pharm Co., Ltd.
4.13.1 Profile
4.13.2 Vaccine Business
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.15 Dalian Aleph Biomedical Co., Ltd.
4.15.1 Profile
4.15.2 Vaccine Business
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.17.1 Profile
4.17.2 Operation
4.18 Other Enterprises
4.18.1 Xiamen Innovax Biotech Co., Ltd.
4.18.2 Convac Biotechnology Co., Ltd.
4.18.3 Chengdu Kanghua Biological Products Co.,Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc. 

5 Summary and Forecast 
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated 
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth 
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 Human Papillomavirus (HPV) Vaccine Market is Promising 
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2010-2017
Global Human Vaccine Market Size, 2017-2022E
Revenue of Major Global Vaccine Companies, 2013-2017
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2017
Related Policies in China Human Vaccine Industry, 2006-2017
Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2017
Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2022E
EPI Human Vaccine Varieties in China
Lot Release Volume of Human Vaccine in China, 2013-2018
Top10 Human Vaccines by Lot Release Volume in China, 2013-2018
Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, Jan.-Sep. 2018
China Human Vaccine Market Size, 2010-2018
Import Volume and Value of Human Vaccine in China, 2010-2017
Export Volume and Value of Human Vaccine in China, 2010-2017
Average Unit Export/Import Price of Human Vaccine in China, 2010-2017
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2017
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, Jan.-Sep.2018
Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2014-2018
Lot Release Volume of Human Vaccines in China by Enterprise, 2017
Lot Release Volume of Human Vaccines in China by Enterprise, Jan.-Sep.2018
Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2018
Hepatitis B Morbidity and Mortality in China, 2013-2017
Hepatitis B Morbidity and Mortality in China, Jan.-Sep.2018
Lot Release Volume of Hepatitis B Vaccine in China, 2013-2018
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2018
Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2018
Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2018
Meningitis Morbidity and Mortality in China, 2013-2017
Meningitis Morbidity and Mortality in China, Jan.-Sep. 2018
Meningococcal Vaccines Lot Release Volume in China, 2013-2018
Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2018
Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2018
Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2018
Hepatitis A Morbidity and Mortality in China, 2013-2017
Hepatitis A Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Hepatitis A Vaccine in China, 2013-2018
Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2018
Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2018
Influenza Morbidity and Mortality in China, 2013-2017
Influenza Morbidity and Mortality in China, Jan.-Sep. 2018
H7N9 Influenza Morbidity and Mortality in China, 2013-2017
H7N9 Influenza Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Influenza Vaccine in China, 2013-2018
Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2018
Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Hib Vaccine in China, 2013-2018
Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2018
Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2018
Rabies Morbidity and Mortality in China, 2013-2017
Rabies Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Human Rabies Vaccine in China, 2013-2018
Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2018
Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Varicella Vaccine in China, 2013-2018
Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2018
Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Pneumococcal Vaccines in China, 2013-2018
Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2018
Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2018
Pertussis Morbidity and Mortality in China, 2012-2017
Pertussis Morbidity and Mortality in China, Jan.-Sep. 2018
Neonatal Tetanus Morbidity and Mortality in China, 2012-2017
Neonatal Tetanus Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of DTP Vaccine in China, 2013-2018
Lot Release Volume of Major DTP Vaccine Companies in China, 2013-2018
Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2018
Poliomyelitis Morbidity and Mortality in China, 2013-2018
Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2018
Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2018
Hepatitis E Morbidity and Mortality in China, 2012-2017
Hepatitis E Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Hepatitis E Vaccine in China, 2013-2018
Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2018
Specifications and Place of Origin of China National Biotech Group’s Main Vaccine Products  
Revenue and Net Income of Beijing Tiantan Biological Products, 2013-2018
Revenue Breakdown of Beijing Tiantan Biological Products by Product, 2013-2017
Revenue Structure of Beijing Tiantan Biological Products by Product, 2013-2017
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2013-2017
Revenue Structure of Beijing Tiantan Biological Products by Region, 2013-2017
Gross Margin of Beijing Tiantan Biological Products by Product, 2013-2017
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2018
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2017
Revenue and Net Income of Hualan Biological Engineering, 2013-2018
Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2018
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2017
Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2018
Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes 
Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2018
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2017
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2017
Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2018
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2018
Projects under Registration Process of Chongqing Zhifei Biological Products, as of 2018H1
Progress of Preclinical Projects of Chongqing Zhifei Biological Products by 2018H1
Revenue and Net Income of Walvax Biotechnology, 2013-2018
Revenue Breakdown of Walvax Biotechnology by Product, 2014-2017
Revenue Breakdown of Walvax Biotechnology by Region, 2014-2017
Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2017
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2018
Progress of Walvax Biotechnology’s Projects with Raised Fund, as of 2018 H1
Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2018H1
Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2017
Lot Release Volume of Walvax Biotechnology, 2014-2018
Revenue and Net Income of Liaoning Chengda, 2013-2018
Revenue Breakdown of Liaoning Chengda by Product, 2013-2018
Revenue Structure of Liaoning Chengda by Product, 2013-2018
Gross Margin of Liaoning Chengda, 2013-2018
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2015-2017
R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2017
Main Products and Their Purposes of Shenzhen Kangtai Biological Products  
Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2017
Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2018
Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2018
Gross Margin of Shenzhen Kangtai Biological Products, 2013-2017
R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2018
Progress of Research Projects of Shenzhen Kangtai Biological Products, as of 2018H1
Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2018H1
Revenue and Net Income of Changsheng Bio-technology, 2014-2017
Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2017
Revenue Structure of Changsheng Bio-technology by Product, 2014-2017
Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2017
Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2017
R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2017
Development Course of Olymvax Biopharmaceuticals
Revenue and Net Income of Olymvax Biopharmaceuticals, 2014-2018
Research Progress of Products Developed by Olymvax Biopharmaceuticals
Main Products of Sinovac Biotech
Revenue and Net Income of Sinovac Biotech, 2013-2017
Revenue Breakdown of Sinovac Biotech by Product, 2013-2017
Equity Structured of Sinovac Biotech
Financial Indices of Sinovac Biotech, 2015-2017
Financial Indices of Changchun BCHT Biotechnology, 2014-2018
Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2018
Development Goals of Dalian Aleph Biomedical 
Financial Indices of Beijing Minhai Biotechnology, 2015-2018
Development Course of Xiamen Innovax Biotech
Main Partners of CanSino Biologics
Products Being Researched by CanSino Biologics
China’s Vaccine Market Size, 2017-2022E
Number of Newborns in China, 2015-2022E
China’s Population Aged over 60 and % of Total Population, 2009-2017 
Global Incidence of Cervical Cancer
HPV Vaccine Products Worldwide
Global HPV Vaccine Market Size, 2006-2015
Lot Release Volume of HPV Vaccine in China by Enterprise, Jan-Sept 2018
Major HPV Vaccine Developers in China and Their Progress
Major 13-valent Pneumococcal Conjugate Vaccine Developers in China and Their Progress
R&D Investment of Major Vaccine Companies in China, 2013-2018
Main Vaccine Products Being Researched by Companies in China and Their Progress 

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统